Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017, Article ID 7687851, 19 pages
https://doi.org/10.1155/2017/7687851
Review Article

Metabolic Footprints and Molecular Subtypes in Breast Cancer

1Department of Applied Research and Technical Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
2Core Facilities, High Resolution NMR Unit, Istituto Superiore di Sanità, Rome, Italy

Correspondence should be addressed to Vera Cappelletti; ti.im.iromutotutitsi@ittelleppac.arev

Received 24 July 2017; Accepted 11 October 2017; Published 24 December 2017

Academic Editor: Paul Span

Copyright © 2017 Vera Cappelletti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. V. Jensen and V. C. Jordan, “The estrogen receptor,” Clinical Cancer Research, vol. 9, no. 6, pp. 1980–1989, 2003. View at Google Scholar
  2. G. W. Sledge and W. L. McGuire, “Steroid hormone receptors in human breast cancer,” Advances in Cancer Research, vol. 38, pp. 61–75, 1983. View at Publisher · View at Google Scholar
  3. F. de Waard, “Premenopausal and postmenopausal breast cancer: one disease or two?” Journal of the National Cancer Institute, vol. 63, no. 3, pp. 549–552, 1979. View at Publisher · View at Google Scholar · View at Scopus
  4. O. W. Kamel, W. A. Franklin, J. C. Ringus, and J. S. Meyer, “Thymidine labeling index and Ki-67 growth fraction in lesions of the breast,” American Journal of Pathology, vol. 134, no. 1, pp. 107–113, 1989. View at Google Scholar
  5. C. M. Perou, T. Sørlie, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Curtis, S. P. Shah, S. F. Chin et al., “The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups,” Nature, vol. 486, no. 7403, pp. 346–352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Parker, M. Mullins, M. C. Cheang et al., “Supervised risk predictor of breast cancer based on intrinsic subtypes,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1160–1167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. The Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours,” Nature, vol. 490, no. 7418, pp. 61–70, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. L. N. Harris, N. Ismaila, L. M. McShane et al., “Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline,” Journal of Clinical Oncology, vol. 34, no. 10, pp. 1134–1150, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. A. S. Coates, E. P. Winer, A. Goldhirsch et al., “Tailoring therapies—improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015,” Annals of Oncology, vol. 26, no. 8, pp. 1533–1546, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Sørlie, “Molecular portraits of breast cancer: tumour subtypes as distinct disease entities,” European Journal of Cancer, vol. 40, no. 18, pp. 2667–2675, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Prat, B. Adamo, C. Fan et al., “Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity,” Scientific Reports, vol. 3, no. 1, p. 3544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. K. A. Hoadley, C. Yau, D. M. Wolf et al., “Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin,” Cell, vol. 158, no. 4, pp. 929–944, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Pavlova and C. Thompson, “The emerging hallmarks of cancer metabolism,” Cell Metabolism, vol. 23, no. 1, pp. 27–47, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. O. Warburg, F. Wind, and E. Negelein, “The metabolism of tumor in the body,” The Journal of General Physiology, vol. 8, no. 6, pp. 519–530, 1927. View at Publisher · View at Google Scholar
  18. T. Soga, “Cancer metabolism: key players in metabolic reprogramming,” Cancer Science, vol. 104, no. 3, pp. 275–281, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. C. Patra and N. Hay, “The pentose phosphate pathway and cancer,” Trends in Biochemical Sciences, vol. 39, no. 8, pp. 347–354, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. R. Eberhardy and P. J. Farnham, “c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism,” Journal of Biological Chemistry, vol. 276, no. 51, pp. 48562–48571, 2001. View at Publisher · View at Google Scholar
  21. J. Pérez-Escuredo, R. K. Dadhich, S. Dhup et al., “Lactate promotes glutamine uptake and metabolism in oxidative cancer cells,” Cell Cycle, vol. 15, no. 1, pp. 72–83, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. J. R. Mayers and M. G. Vander Heiden, “Nature and nurture: what determines tumor metabolic phenotypes?” Cancer Research, vol. 77, no. 12, pp. 3131–3134, 2017. View at Publisher · View at Google Scholar
  23. G. S. Ducker and J. D. Rabinowitz, “One-carbon metabolism in health and disease,” Cell Metabolism, vol. 25, no. 1, pp. 27–42, 2017. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Amelio, F. Cutruzzolá, A. Antonov, M. Agostini, and G. Melino, “Serine and glycine metabolism in cancer,” Trends in Biochemical Sciences, vol. 39, no. 4, pp. 191–198, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. A. C. Newman and O. D. K. Maddocks, “One-carbon metabolism in cancer,” British Journal of Cancer, vol. 116, no. 12, pp. 1499–1504, 2017. View at Publisher · View at Google Scholar
  26. E. Ananieva, “Targeting amino acid metabolism in cancer growth and anti-tumor immune response,” World Journal of Biological Chemistry, vol. 6, no. 4, pp. 281–289, 2015. View at Publisher · View at Google Scholar
  27. S. Gupta, A. Roy, and B. S. Dwarakanath, “Metabolic cooperation and competition in the tumor microenvironment: implications for therapy,” Frontiers in Oncology, vol. 7, p. 68, 2017. View at Publisher · View at Google Scholar
  28. A. L. Mellor and D. H. Munn, “IDO expression by dendritic cells: tolerance and tryptophan catabolism,” Nature Reviews Immunology, vol. 4, no. 10, pp. 762–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. A. L. Mellor and D. H. Munn, “Tryptophan catabolism and regulation of adaptive immunity,” The Journal of Immunology, vol. 170, no. 12, pp. 5809–5813, 2003. View at Publisher · View at Google Scholar
  30. A. L. Mellor and D. H. Munn, “Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?” Immunology Today, vol. 20, no. 10, pp. 469–473, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Geiger, J. C. Rieckmann, T. Wolf et al., “L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity,” Cell, vol. 167, no. 3, pp. 829–842.e13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Glunde, Z. M. Bhujwalla, and S. M. Ronen, “Choline metabolism in malignant transformation,” Nature Reviews Cancer, vol. 11, no. 12, p. 835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Podo, S. Canevari, R. Canese, M. E. Pisanu, A. Ricci, and E. Iorio, “MR evaluation of response to targeted treatment in cancer cells,” NMR in Biomedicine, vol. 24, no. 6, pp. 648–672, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Beloribi-Djefaflia, S. Vasseur, and F. Guillaumond, “Lipid metabolic reprogramming in cancer cells,” Oncogenesis, vol. 5, no. 1, article e189, 2016. View at Publisher · View at Google Scholar
  35. C. R. Santos and A. Schulze, “Lipid metabolism in cancer,” The FEBS Journal, vol. 279, no. 15, pp. 2610–2623, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Furuta, S. K. Pai, R. Zhan et al., “Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1,” Cancer Research, vol. 68, no. 4, pp. 1003–1011, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. D. E. Bauer, G. Hatzivassiliou, F. Zhao, C. Andreadis, and C. B. Thompson, “ATP citrate lyase is an important component of cell growth and transformation,” Oncogene, vol. 24, no. 41, pp. 6314–6322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Carracedo, L. C. Cantley, and P. P. Pandolfi, “Cancer metabolism: fatty acid oxidation in the limelight,” Nature Reviews Cancer, vol. 13, no. 4, pp. 227–232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Chiarugi, C. Dölle, R. Felici, and M. Ziegler, “The NAD metabolome — a key determinant of cancer cell biology,” Nature Reviews Cancer, vol. 12, no. 11, pp. 741–752, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Yue, J. Li, S. Y. Lee et al., “Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness,” Cell Metabolism, vol. 19, no. 3, pp. 393–406, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Guillaumond, G. Bidaut, M. Ouaissi et al., “Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 8, pp. 2473–2478, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. P. T. Bozza and J. P. B. Viola, “Lipid droplets in inflammation and cancer,” Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 82, no. 4–6, pp. 243–250, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. D. de Gonzalo-Calvo, L. López-Vilaró, L. Nasarre et al., “Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study,” BMC Cancer, vol. 15, p. 460, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Podo, L. Paris, S. Cecchetti et al., “Activation of phosphatidylcholine-specific phospholipase C in breast and ovarian cancer: impact on MRS-detected choline metabolic profile and perspectives for targeted therapy,” Frontiers in Oncology, vol. 6, p. 171, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Cooper, K. Maupin, and N. Merrill, “Origins of cancer symposium 2015: posttranslational modifications and cancer,” Genes & Cancer, vol. 6, no. 7-8, p. 303, 2015. View at Publisher · View at Google Scholar
  46. R. D. Cummings and J. M. Pierce, “The challenge and promise of glycomics,” Chemistry & Biology, vol. 21, no. 1, pp. 1–15, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. S. S. Pinho and C. A. Reis, “Glycosylation in cancer: mechanisms and clinical implications,” Nature Reviews Cancer, vol. 15, no. 9, pp. 540–555, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. Y.-Y. Shih and C.-H. Lin, “S-Glutathionylation promotes HSP90 degradation under oxidative stress,” The FASEB Journal, vol. 29, 1 Supplement, pp. 717–726, 2015. View at Google Scholar
  49. S. R. Stowell, T. Ju, and R. D. Cummings, “Protein glycosylation in cancer,” Annual Review of Pathology: Mechanisms of Disease, vol. 10, no. 1, pp. 473–510, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Dutta, C. Mandal, and C. Mandal, “Unusual glycosylation of proteins: beyond the universal sequon and other amino acids,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1861, pp. 3096–3108, 2017. View at Publisher · View at Google Scholar
  51. W.-L. Ho, W.-M. Hsu, M.-C. Huang, K. Kadomatsu, and A. Nakagawara, “Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma,” Journal of Hematology & Oncology, vol. 9, no. 1, p. 100, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. U. L. Günther, “Metabolomics biomarkers for breast cancer,” Pathobiology, vol. 82, no. 3-4, pp. 153–165, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. I. S. Gribbestad, H. E. Fjösne, O. A. Haugen et al., “In vitro proton NMR spectroscopy of extracts from human breast tumours and non-involved breast tissue,” Anticancer Research, vol. 13, no. 6A, pp. 1973–1980, 1993. View at Google Scholar
  54. W. B. Mackinnon, P. A. Barry, P. L. Malycha et al., “Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy,” Radiology, vol. 204, no. 3, pp. 661–666, 1997. View at Publisher · View at Google Scholar
  55. L. L. Cheng, I.-W. Chang, B. L. Smith, and R. G. Gonzalez, “Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy,” Journal of Magnetic Resonance, vol. 135, no. 1, pp. 194–202, 1998. View at Publisher · View at Google Scholar
  56. C. E. Mountford, R. L. Somorjai, P. Malycha et al., “Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy,” British Journal of Surgery, vol. 88, no. 9, pp. 1234–1240, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Sitter, S. Lundgren, T. F. Bathen, J. Halgunset, H. E. Fjosne, and I. S. Gribbestad, “Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters,” NMR in Biomedicine, vol. 19, no. 1, pp. 30–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Budczies, C. Denkert, B. M. Müller et al., “Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue – a GC-TOFMS based metabolomics study,” BMC Genomics, vol. 13, no. 1, p. 334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. T. F. Bathen, B. Geurts, B. Sitter et al., “Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery,” PLoS One, vol. 8, no. 4, article e61578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Borgan, B. Sitter, O. C. Lingjærde et al., “Merging transcriptomics and metabolomics - advances in breast cancer profiling,” BMC Cancer, vol. 10, no. 1, p. 628, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. T. H. Haukaas, S. A. Moestue, R. Vettukattil et al., “Impact of freezing delay time on tissue samples for metabolomic studies,” Frontiers in Oncology, vol. 6, p. 17, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Veneroni, M. Dugo, M. G. Daidone et al., “Applicability of under vacuum fresh tissue sealing and cooling to omics analysis of tumor tissues,” Biopreservation and Biobanking, vol. 14, no. 6, pp. 480–490, 2016. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Tibshirani, T. Hastie, B. Narasimhan, and G. Chu, “Diagnosis of multiple cancer types by shrunken centroids of gene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 10, pp. 6567–6572, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. S. O. Lim, C. W. Li, W. Xia et al., “EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape,” Cancer Research, vol. 76, no. 5, pp. 1284–1296, 2016. View at Publisher · View at Google Scholar · View at Scopus
  65. J. Choi, W.-H. Jung, and J. S. Koo, “Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry,” Pathobiology, vol. 80, no. 1, pp. 41–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. R. Hussein, S. Bandyopadhyay, A. Semaan et al., “Glut-1 expression correlates with basal-like breast cancer,” Translational Oncology, vol. 4, no. 6, pp. 321–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. M. Kanaan, B. P. Sampey, D. Beyene et al., “Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease,” Cancer Genomics Proteomics, vol. 11, no. 6, pp. 279–294, 2014. View at Google Scholar
  68. C. Pinheiro, B. Sousa, A. Albergaria et al., “GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression,” Histology and Histopathology, vol. 26, no. 10, pp. 1279–1286, 2011. View at Publisher · View at Google Scholar
  69. L. Jin, J. Chun, C. Pan et al., “Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis,” Oncogene, vol. 36, no. 27, pp. 3797–3806, 2017. View at Publisher · View at Google Scholar
  70. M. V. Liberti and J. W. Locasale, “The Warburg effect: how does it benefit cancer cells?” Trends in Biochemical Sciences, vol. 41, no. 3, pp. 211–218, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. V. Launonen, O. Vierimaa, M. Kiuru et al., “Inherited susceptibility to uterine leiomyomas and renal cell cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 6, pp. 3387–3392, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. H. J. Lehtonen, M. Kiuru, S. K. Ylisaukko-Oja et al., “Increased risk of cancer in patients with fumarate hydratase germline mutation,” Journal of Medical Genetics, vol. 43, no. 6, pp. 523–526, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. C.-C. Hsu, L.-M. Tseng, and H.-C. Lee, “Role of mitochondrial dysfunction in cancer progression,” Experimental Biology and Medicine, vol. 241, no. 12, pp. 1281–1295, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Morin, E. Letouzé, A.-P. Gimenez-Roqueplo, and J. Favier, “Oncometabolites-driven tumorigenesis: from genetics to targeted therapy,” International Journal of Cancer, vol. 135, no. 10, pp. 2237–2248, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. A. T. Fathi, H. Sadrzadeh, A. H. Comander et al., “Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate,” The Oncologist, vol. 19, no. 6, pp. 602–607, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Terunuma, N. Putluri, P. Mishra et al., “MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis,” The Journal of Clinical Investigation, vol. 124, no. 1, pp. 398–412, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Chowdhury, K. K. Yeoh, Y. M. Tian et al., “The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases,” EMBO Reports, vol. 12, no. 5, pp. 463–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. W. Xu, H. Yang, Y. Liu et al., “Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases,” Cancer Cell, vol. 19, no. 1, pp. 17–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Holm, C. Hegardt, J. Staaf et al., “Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns,” Breast Cancer Research, vol. 12, no. 3, article R36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Holm, J. Staaf, M. Lauss et al., “An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells,” Breast Cancer Research, vol. 18, no. 1, p. 27, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. C. T. Hensley, A. T. Wasti, and R. J. DeBerardinis, “Glutamine and cancer: cell biology, physiology, and clinical opportunities,” The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3678–3684, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. Y. H. Ko, Z. Lin, N. Flomenberg et al., “Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells,” Cancer Biology & Therapy, vol. 12, no. 12, pp. 1085–1097, 2011. View at Publisher · View at Google Scholar
  83. J.-P. Long, X.-N. Li, and F. Zhang, “Targeting metabolism in breast cancer: how far we can go?” World Journal of Clinical Oncology, vol. 7, no. 1, pp. 122–130, 2016. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Kim, D. H. Kim, W.-H. Jung, and J. S. Koo, “Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer,” Endocrine Related Cancer, vol. 20, no. 3, pp. 339–348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. M. D. Cao, S. Lamichhane, S. Lundgren et al., “Metabolic characterization of triple negative breast cancer,” BMC Cancer, vol. 14, no. 1, p. 941, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. V. M. Asiago, N. Z. Alvarado, N. Shanaiah et al., “Abstract P3-10-18: early detection of recurrent breast cancer using metabolite profiling,” Cancer Research, vol. 70, no. 21, pp. 8309–8318, 2010. View at Publisher · View at Google Scholar
  87. J. Budczies, B. M. Pfitzner, B. Györffy et al., “Glutamate enrichment as new diagnostic opportunity in breast cancer,” International Journal of Cancer, vol. 136, no. 7, pp. 1619–1628, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. N. E. Simpson, V. P. Tryndyak, F. A. Beland, and I. P. Pogribny, “An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression,” Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 959–968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. D. K. Nomura, J. Z. Long, S. Niessen, H. S. Hoover, S.-W. Ng, and B. F. Cravatt, “Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis,” Cell, vol. 140, no. 1, pp. 49–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. X. Luo, C. Cheng, Z. Tan et al., “Emerging roles of lipid metabolism in cancer metastasis,” Molecular Cancer, vol. 16, no. 1, p. 76, 2017. View at Publisher · View at Google Scholar
  91. F. Röhrig and A. Schulze, “The multifaceted roles of fatty acid synthesis in cancer,” Nature Reviews Cancer, vol. 16, no. 11, pp. 732–749, 2016. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Nath and C. Chan, “Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers,” Scientific Reports, vol. 6, no. 1, article 18669, 2016. View at Publisher · View at Google Scholar · View at Scopus
  93. W. B. Kinlaw, P. W. Baures, L. E. Lupien, W. L. Davis, and N. B. Kuemmerle, “Fatty acids and breast cancer: make them on site or have them delivered,” Journal of Cellular Physiology, vol. 231, no. 10, pp. 2128–2141, 2016. View at Publisher · View at Google Scholar · View at Scopus
  94. M. E. Monaco, “Fatty acid metabolism in breast cancer subtypes,” Oncotarget, vol. 8, no. 17, pp. 29487–29500, 2017. View at Publisher · View at Google Scholar
  95. N. Thapa, S. Choi, X. Tan, T. Wise, and R. A. Anderson, “Phosphatidylinositol phosphate 5-kinase Iγ and phosphoinositide 3-kinase/Akt signaling couple to promote oncogenic growth,” Journal of Biological Chemistry, vol. 290, no. 30, pp. 18843–18854, 2015. View at Publisher · View at Google Scholar · View at Scopus
  96. L. Paris, S. Cecchetti, F. Spadaro et al., “Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells,” Breast Cancer Research, vol. 12, no. 3, article R27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. T. Miyake and S. J. Parsons, “Functional interactions between choline kinase α, epidermal growth factor receptor and c-Src in breast cancer cell proliferation,” Oncogene, vol. 31, no. 11, pp. 1431–1441, 2012. View at Publisher · View at Google Scholar · View at Scopus
  98. P. E. Porporato, S. Dhup, R. K. Dadhich, T. Copetti, and P. Sonveaux, “Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review,” Frontiers in Pharmacology, vol. 2, p. 49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. B. F. Clem, J. O’Neal, G. Tapolsky et al., “Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer,” Molecular Cancer Therapeutics, vol. 12, no. 8, pp. 1461–1470, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Dart, “Tumour metabolism: lactic acid: not just a waste product?” Nature Reviews Cancer, vol. 16, no. 11, pp. 676-677, 2016. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Le, C. R. Cooper, A. M. Gouw et al., “Inhibition of lactate dehydrogenase a induces oxidative stress and inhibits tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 5, pp. 2037–2042, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Xie, V. A. Valera, M. J. Merino et al., “LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer,” Molecular Cancer Therapeutics, vol. 8, no. 3, pp. 626–635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Yu, J. A. Deck, L. A. Hunsaker et al., “Selective active site inhibitors of human lactate dehydrogenases A4, B4, and C4,” Biochemical Pharmacology, vol. 62, no. 1, pp. 81–89, 2001. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Sonveaux, F. Végran, T. Schroeder et al., “Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice,” The Journal of Clinical Investigation, vol. 118, no. 12, pp. 3930–3942, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Fulda, L. Galluzzi, and G. Kroemer, “Targeting mitochondria for cancer therapy,” Nature Reviews Drug Discovery, vol. 9, no. 6, pp. 447–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. G. Kroemer and J. Pouyssegur, “Tumor cell metabolism: cancer’s Achilles’ heel,” Cancer Cell, vol. 13, no. 6, pp. 472–482, 2008. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Hilvo, C. Denkert, L. Lehtinen et al., “Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression,” Cancer Research, vol. 71, no. 9, pp. 3236–3245, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. J. A. Menendez and R. Lupu, “Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis,” Nature Reviews Cancer, vol. 7, no. 10, pp. 763–777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. L. S. Pike, A. L. Smift, N. J. Croteau, D. A. Ferrick, and M. Wu, “Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells,” Biochimica et Biophysica Acta (BBA) - Bioenergetics, vol. 1807, no. 6, pp. 726–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. K. Zaugg, Y. Yao, P. T. Reilly et al., “Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress,” Genes & Development, vol. 25, no. 10, pp. 1041–1051, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. G. C. Prendergast, C. Smith, S. Thomas et al., “Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer,” Cancer Immunology, Immunotherapy, vol. 63, no. 7, pp. 721–735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. J. R. Moffett and M. A. Namboodiri, “Tryptophan and the immune response,” Immunology and Cell Biology, vol. 81, no. 4, pp. 247–265, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. Y. W. Moon, J. Hajjar, P. Hwu, and A. Naing, “Targeting the indoleamine 2,3-dioxygenase pathway in cancer,” Journal for ImmunoTherapy of Cancer, vol. 3, no. 1, p. 51, 2015. View at Publisher · View at Google Scholar · View at Scopus
  114. B. Sitter, T. F. Bathen, T. E. Singstad et al., “Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy,” NMR in Biomedicine, vol. 23, no. 4, pp. 424–431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. M. D. Cao, B. Sitter, T. F. Bathen et al., “Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling,” NMR in Biomedicine, vol. 25, no. 2, pp. 369–378, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. G. F. Giskeødegård, S. Lundgren, B. Sitter et al., “Lactate and glycine—potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers,” NMR in Biomedicine, vol. 25, no. 11, pp. 1271–1279, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. M. D. Cao, G. F. Giskeødegård, T. F. Bathen et al., “Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy,” BMC Cancer, vol. 12, no. 1, p. 39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Ye, A. Mancuso, X. Tong et al., “Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 18, pp. 6904–6909, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Galluzzi, O. Kepp, M. G. Vander Heiden, and G. Kroemer, “Metabolic targets for cancer therapy,” Nature Reviews Drug Discovery, vol. 12, no. 11, pp. 829–846, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. M. J. Khandekar, P. Cohen, and B. M. Spiegelman, “Molecular mechanisms of cancer development in obesity,” Nature Reviews Cancer, vol. 11, no. 12, pp. 886–895, 2011. View at Publisher · View at Google Scholar · View at Scopus
  121. M. Pollak, “The insulin and insulin-like growth factor receptor family in neoplasia: an update,” Nature Reviews Cancer, vol. 12, no. 3, pp. 159–169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” BMJ, vol. 330, no. 7503, pp. 1304-1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. D. Li, S.-C. J. Yeung, M. M. Hassan, M. Konopleva, and J. L. Abbruzzese, “Antidiabetic therapies affect risk of pancreatic cancer,” Gastroenterology, vol. 137, no. 2, pp. 482–488, 2009. View at Publisher · View at Google Scholar · View at Scopus